Palliative Care for Lichen Planus

Treatment Approach

The American Academy of Dermatology recommends high-potency topical corticosteroids, specifically clobetasol propionate 0.05% gel for oral lesions or clobetasol 0.05% cream/ointment for cutaneous disease, as the cornerstone of palliative treatment for lichen planus, applied twice daily for 2-3 months followed by gradual tapering 1, 2
For oral lichen planus, the first-line palliative approach is to apply clobetasol 0.05% gel or fluocinonide 0.05% gel to dried oral mucosa twice daily 1, 2
Gel formulations are mandatory for oral disease, as they provide appropriate adherence, and treatment should continue for 2-3 months until symptoms improve to Grade 1, then taper gradually over 3 weeks to prevent rebound flares 1, 2
The European Academy of Dermatology and Venereology suggests that alternative formulations, such as clobetasol 0.05% ointment mixed in 50% Orabase, can be applied twice weekly for localized oral lesions 2
Adjunctive palliative measures for symptom control include compound benzocaine gel applied topically for severe pain, 0.1% chlorhexidine gargling solution to reduce inflammation and prevent secondary infection, and oral antihistamines for moderate to severe disease 1, 2
A short course of oral prednisone 15-30 mg for 3-5 days can be used for acute severe flares 2
When corticosteroids fail or are contraindicated, tacrolimus 0.1% ointment can be used as an alternative first-line option 1, 2

The National Institute for Health and Care Excellence advises against abruptly discontinuing topical corticosteroids, and recommends tapering gradually over 3 weeks to prevent rebound flares 1, 2
The American Academy of Dermatology warns against using cream or ointment formulations for oral mucosal disease, as only gel formulations provide appropriate adherence for intraoral lesions 2
The European Academy of Dermatology and Venereology recommends monitoring patients using potent steroids to avoid potential side effects, including cutaneous atrophy, adrenal suppression, hypopigmentation, and contact sensitivity 3
Patients should be advised to wash hands thoroughly after application to avoid spreading medication to sensitive areas like eyes 3

The British Association of Dermatologists recommends scheduling follow-up at 3 months to assess treatment response, ensure proper medication use, and monitor for adverse effects 3, 4
If response is satisfactory, a final assessment should be conducted at 6 months before discharge to primary care 4
Patients should be instructed to report any persistent ulceration or new growth, as oral lichen planus carries a small risk of malignant transformation to squamous cell carcinoma 4